Form 4: HCA Healthcare SVP & Controller Granted SARs

HCA Healthcare's SVP & Controller, Christopher F. Wyatt, was granted 2,560 Stock Appreciation Rights with a vesting schedule beginning in 2027.

Summary

• Christopher F. Wyatt, SVP & Controller of HCA Healthcare, Inc., was granted 2,560 Stock Appreciation Rights (SARs).
• The SARs have an exercise price of $482.53.
• The vesting schedule for these SARs begins on January 29, 2027, with four equal annual installments.
• The SARs will expire on January 29, 2036.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• A Power of Attorney, effective July 31, 2025, authorizes specific individuals to file SEC forms on behalf of Christopher F. Wyatt.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the grant of equity ties executive compensation directly to the company's stock performance, fostering alignment with shareholder interests.

Positives

• The grant of Stock Appreciation Rights aligns the executive's interests with shareholder value creation.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary transaction.

Risks

• The Power of Attorney explicitly states that neither HCA Healthcare nor the attorneys-in-fact assume liability for the undersigned's responsibility to comply with Exchange Act requirements, any failure to comply, or profit disgorgement under Section 16(b) of the Exchange Act.
• The Power of Attorney does not relieve the undersigned from responsibility for compliance with obligations under the Exchange Act, including reporting requirements under Section 16.

Future Outlook

The granted Stock Appreciation Rights will vest in four equal annual installments, commencing on January 29, 2027, and will expire on January 29, 2036.

Management Comments

• "This Power of Attorney authorizes, but does not require, such attorneys-in-fact to act in their discretion on information provided to such attorneys-in-fact without independent verification of such information."
• "Neither the Company nor such attorneys-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act."
• "This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act."

Industry Context

StockSavvy.ai notes that grants of Stock Appreciation Rights are a common form of executive compensation in the healthcare industry, designed to incentivize long-term performance and align executive interests with shareholder returns, similar to practices at peers like Tenet Healthcare or Community Health Systems.

Comparison to Industry Standards

• The grant of Stock Appreciation Rights (SARs) is a standard component of executive compensation packages across various industries, including healthcare, aligning executive incentives with stock price performance.
• The vesting schedule of four equal annual installments is a typical structure for long-term incentive awards, comparable to practices observed at major healthcare providers such as Universal Health Services or DaVita Inc., which often use multi-year vesting to encourage retention and sustained performance.
• The use of a Rule 10b5-1 plan for such transactions is a best practice for corporate insiders, providing an affirmative defense against insider trading allegations by pre-scheduling trades.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of SARs aligns the interests of a key executive with shareholders, as the value of the SARs is tied to the company's stock price performance.
• Employees: No direct impact on general employees is indicated.
• Management: The Power of Attorney facilitates compliance for the reporting person and the company's legal/compliance team.

Next Steps

• The Stock Appreciation Rights will begin to vest in four equal annual installments starting January 29, 2027.
• The reporting person will continue to hold the SARs until their expiration on January 29, 2036, or until exercised.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a senior executive, which is a standard component of compensation and aligns management incentives with shareholder value. It does not present new information that would fundamentally alter the investment thesis for HCA Healthcare, thus a 'hold' recommendation is appropriate for existing investors, while new investors should consider broader company fundamentals.

Keywords

HCA Healthcare, HCA, Stock Appreciation Rights, SARs, Insider Transaction, Executive Compensation, Form 4, Rule 10b5-1, Christopher F. Wyatt